NCT06648850View on ClinicalTrials.gov

Clinical Study of DA-001 as a Treatment for Telogen Effluvium

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 16, 2026

Study Completion Date

April 17, 2026

Conditions
Telogen Effluvium
Interventions
DRUG

DA-001

Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution

OTHER

Placebo

Placebo Topical Solution

DRUG

Phenylephrine

Phenylephrine Topical Solution

OTHER

Intact5

Cosmetic formulation containing bitter orange extract

Sponsors
All Listed Sponsors
collaborator

Follea International Limited

INDUSTRY

collaborator

Daniel Alain, Inc.

UNKNOWN

lead

Applied Biology, Inc.

INDUSTRY